255 related articles for article (PubMed ID: 32695231)
1. Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario.
Zingone F; Barberio B; Compostella F; Girardin G; D'Incà R; Marinelli C; Marsilio I; Lorenzon G; Savarino EV
Therap Adv Gastroenterol; 2020; 13():1756284820936536. PubMed ID: 32695231
[TBL] [Abstract][Full Text] [Related]
2. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
[TBL] [Abstract][Full Text] [Related]
4. Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn's Disease and Ulcerative Colitis.
Merza N; Nawras Y; Saab O; Dahiya DS; Ahmed Z; Ranabothu M; Boujemaa S; Hassan M; Kobeissy A; Lilley K
Gastroenterology Res; 2023 Dec; 16(6):289-306. PubMed ID: 38186583
[TBL] [Abstract][Full Text] [Related]
5. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.
Moens A; Verstockt B; Alsoud D; Sabino J; Ferrante M; Vermeire S
Inflamm Bowel Dis; 2022 Aug; 28(8):1135-1142. PubMed ID: 34751766
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.
Macaluso FS; Fries W; Renna S; Viola A; Muscianisi M; Cappello M; Guida L; Siringo S; Camilleri S; Garufi S; Privitera AC; Belluardo N; Giangreco E; Bertolami C; Vassallo R; Rizzuto G; Orlando R; Ventimiglia M; Orlando A;
United European Gastroenterol J; 2020 Nov; 8(9):1045-1055. PubMed ID: 32772830
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis.
Hu Q; Tang XZ; Liu F; Liu DW; Cao B
Therap Adv Gastroenterol; 2023; 16():17562848231166227. PubMed ID: 37124368
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study.
Visuri I; Eriksson C; Karlqvist S; Lykiardopoulos B; Karlén P; Grip O; Söderman C; Almer S; Hertervig E; Marsal J; Malmgren C; Delin J; Strid H; Sjöberg M; Bergemalm D; Hjortswang H; Halfvarson J
Therap Adv Gastroenterol; 2023; 16():17562848231174953. PubMed ID: 37274297
[TBL] [Abstract][Full Text] [Related]
9. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132
[TBL] [Abstract][Full Text] [Related]
10. Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study.
Lin WC; Tai WC; Chang CH; Tu CH; Feng IC; Shieh MJ; Chung CS; Yen HH; Chou JW; Wong JM; Liu YH; Huang TY; Chuang CH; Tsai TJ; Chiang FF; Lu CY; Hsu WH; Yu FJ; Chao TH; Wu DC; Ho AS; Lin HH; Feng CL; Wu KL; Wong MW; Tung CC; Lin CC; Chen CC; Hu HM; Lu LS; Wang HS; Wu IC; Kuo HY; Wu JF; Yao Shih H; Ni YH; Tang SL; Chen PH; Wei SC
Inflamm Bowel Dis; 2023 Nov; 29(11):1730-1740. PubMed ID: 36626567
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels.
Hüttemann E; Muzalyova A; Gröhl K; Nagl S; Fleischmann C; Ebigbo A; Classen J; Wanzl J; Prinz F; Mayr P; Schnoy E
J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202147
[TBL] [Abstract][Full Text] [Related]
12. P042 Early Versus Later Use of Vedolizumab In IBD: Patient Characteristics And Treatment Patterns In The Real World (RALEE).
Kuharic M; Krugliak Cleveland N; Candela N; Carter J; Qian J; Rusibamayila N; Turpin R; Rubin D
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S11. PubMed ID: 37461960
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers.
Tursi A; Mocci G; Faggiani R; Allegretta L; Valle ND; Medici A; Forti G; Franceschi M; Ferronato A; Gallina S; Grasso G; Larussa T; Luzza F; Lorenzetti R; Penna A; Rodino' S; Sebkova L; Lauria A; Piergallini S; Pranzo G; Scorza S; Zampaletta C; Picchio M; Elisei W
Eur J Intern Med; 2019 Aug; 66():85-91. PubMed ID: 31208827
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
Kim J; Yoon H; Kim N; Lee KM; Jung SA; Choi CH; Kim ES; Jung Y; Eun CS; Kim TO; Kang SB; Kim YS; Seo GS; Lee CK; Im JP; Park SJ; Park DI; Ye BD
Inflamm Bowel Dis; 2021 Nov; 27(12):1931-1941. PubMed ID: 33501935
[TBL] [Abstract][Full Text] [Related]
16. Introducing vedolizumab to clinical practice: who, when, and how?
Bryant RV; Sandborn WJ; Travis SP
J Crohns Colitis; 2015 Apr; 9(4):356-66. PubMed ID: 25687206
[TBL] [Abstract][Full Text] [Related]
17. [Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice].
Shapina MV; Nanaeva BA
Ter Arkh; 2020 Apr; 92(2):67-73. PubMed ID: 32598721
[TBL] [Abstract][Full Text] [Related]
18. Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort.
Buer LCT; Moum BA; Cvancarova M; Warren DJ; Bolstad N; Medhus AW; Høivik ML
Scand J Gastroenterol; 2019 Jan; 54(1):41-48. PubMed ID: 30650312
[TBL] [Abstract][Full Text] [Related]
19. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T
Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease : results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE).
Reenaers C; Cremer A; Dewit O; De Vroey B; Van Moerkercke W; Bossuyt P; Muls V; Imschoot J; Block S; Hantson A; Van Hootegem P
Acta Gastroenterol Belg; 2020; 83(1):15-23. PubMed ID: 32233267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
